Xeris Biopharma HoldingsXERS -3.30%71 Current Ratio is 2.12 as of Mar. 2026, which is 21% below its 10-year median of 2.67. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.19 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,000 Drug Manufacturers companies, Xeris Biopharma Holdings ranks better than 53.1% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Xeris Biopharma Holdings's current ratio for the quarter that ended in Mar. 2026 was 2.12.
Xeris Biopharma Holdings has a current ratio of 2.12. It generally indicates good short-term financial strength.
The historical rank and industry rank for Xeris Biopharma Holdings's Current Ratio or its related term are showing as below:
XERS'
s Current Ratio Range Over the Past 10 Years
Min: 1.64 Med: 2.67 Max: 16.53
Current: 2.12
During the past 10 years, Xeris Biopharma Holdings's highest Current Ratio was 16.53. The lowest was 1.64. And the median was 2.67.
XERS's Current Ratio is ranked better than 53.1% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs XERS: 2.12
Xeris Biopharma Holdings (NAS:XERS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Xeris Biopharma Holdings Current Ratio Related Terms
Xeris Biopharma Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XERS vs PAHC, PRGO, ALVO: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings (XERS) has a Current Ratio of 2.12 as of Mar. 2026. This is 21% below median its historical median of 2.67. Over the past decade, Xeris Biopharma Holdings' Current Ratio has ranged from 1.64 to 16.53. According to the industry distribution chart, Xeris Biopharma Holdings ranks #469 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 46.9%.
Is Xeris Biopharma Holdings' Current Ratio too high?
Xeris Biopharma Holdings' current Current Ratio of 2.12 is 21% below median its 10-year median of 2.67. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 16.53. The Drug Manufacturers industry median Current Ratio is 2.00. Xeris Biopharma Holdings' value of 2.12 is 6% above this industry median. Based on the distribution chart, Xeris Biopharma Holdings ranks #469 out of 1000 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Current Ratio compare to PAHC and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #469 out of 1000 companies for Current Ratio. This puts Xeris Biopharma Holdings in the upper half of its industry. The industry median Current Ratio is 2.00. Xeris Biopharma Holdings' value of 2.12 is 6% above this benchmark. Historically, Xeris Biopharma Holdings' own Current Ratio has ranged from 1.64 to 16.53 over the past decade. While the company's 10-year median is 2.67 vs. the industry median of 2.00, Xeris Biopharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xeris Biopharma Holdings's current Current Ratio of 2.12 is 6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xeris Biopharma Holdings's current Current Ratio is 2.12, which is 21% below median its own 10-year median of 2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.19, compared to a current price of $8.35 — trading 60.9% above its estimated fair value. The current Current Ratio is 2.12, which is 21% below median its 10-year median of 2.67 and 6% above the Drug Manufacturers industry median of 2.00. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Current Ratio is 2.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?
Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued.
The current stock price of $8.35 is trading 60.9% above its estimated GF Value™ of $5.19.
GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.
Key valuation signals for XERS:
Current Ratio: 2.12 (21% below median its 10-year median of 2.67)
GF Value™: $5.19 vs. price of $8.35 (60.9% above fair value)
Industry Position: 6% above the Drug Manufacturers median (#469 of 1000)
No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score
Get the complete analysis for XERS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XERS has been successfully added to your 
